ITMCTR2000003132招募中4 期
Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial
Hubei Hospital of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 75（—）
- 性别
- All
入选标准
- •1. Diagnosed Novel coronavirus pneumonia patients or clinically diagnosed NCP patients in Hubei Province;
- •2. Aged 18 to 65 years;
- •3. The time interval between symptom onset and randomization was within 7 days (the onset of symptom was mainly determined by the time of fever);
- •4. Sign the written informed consent before the study.
排除标准
- •1. There is clear evidence of bacterial infection in respiratory tract infection caused by basic diseases such as primary immunodeficiency disease, congenital respiratory tract malformation, congenital heart disease, gastroesophageal reflux disease and pulmonary dysplasia;
- •2. Subjects with the following conditions: asthma requiring daily treatment, any other chronic respiratory disease, respiratory system bacterial infection such as suppurative tonsillitis, acute bronchitis, sinusitis, otitis media or other respiratory diseases affecting the evaluation of clinical trials. Or with Chest CT confirmed the presence of serious interstitial lung disease, bronchiectasis and other basic lung diseases;
- •3. critically ill patients based on the New Protocol for Diagnosis and Treatment of NCP;
- •4. Severe liver disease (such as child Pugh score >=C, AST > 5 ULN);
- •5. Patients with severe renal insufficiency (estimated glomerular filtration rate <=30ml/min/1.73m2) or continuous renal replacement therapy, hemodialysis or peritoneal dialysis;
- •6. Pregnant or breast-feeding women;
- •7. Patients may be transferred to non-designated hospitals within 72 hours;
- •8. Patients who have participated in other clinical trials in the past 7 days;
- •9. Allergic constitution, such as those who are allergic to two or over twodrugs, with history of food allergies, or known to be allergic to the ingredients of this drug;
- •10. In the opinion of the investigator, subjects who are not suitable for enrollment or with any factors that affect the outcome of the trial.
研究者
相似试验
招募中
4 期
Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trialovel Coronavirus Pneumonia (COVID-19)ITMCTR2000003029Hubei Hospital of Traditional Chinese Medicine
尚未招募
4 期
Efficacy and safety of Jinzhen oral liquid (cough due to phlegmheat) in the treatment of acute bronchitis in children: a randomized, double-bind, parallel controlled, multicentric clinical trialacute bronchitis in childrenITMCTR2000003489Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
招募中
3 期
Efficacy and Safety of Tanreqing Oral Liquid in Treatment of Acute Bronchitis (Phlegm-Heat Obstructing Lungs Syndrome): a multicenter, randomized, double-blind, placebo-controlled trialacute bronchitisITMCTR2100004437West China Hospital, Sichuan University
招募中
4 期
Efficacy and safety of Shenqu Xiaoshi oral liquid in the treatment of children with chronic gastritischronic gastritisITMCTR2100004384The Children's Hospital Zhejiang University Schoor Of Medicine
已完成
2 期
The efficacy and safety of Shuanhuanglian oral solution(child type) in the treatment of acute upper respiratory tract infection (wind-heat-induced syndrome) in children: multicenter, randomized, double-blind, controlled trialAcute upper respiratory tract infection in childrenITMCTR2000003337Affiliated Hospital of Liaoning University of Traditional Chinese Medicine